PLRZ - Biotech Breakouts & Bitcoin Bets

2025-09-12 09:21:05 ET

DENVER, Colo., Sep 12, 2025 ( 247marketnews.com )-  Wall Street is waking up to a red-hot biotech blitz this morning, here’s your top-of-the-morning rundown:

Yesterday’s market star, LIXTE (NASDAQ:LIXT) , is again in the spotlight after blasting through its 52-week high on solid volume. The clinical-stage oncology biotech stunned traders and investors alike with a strategic treasury allocation to cryptocurrency, revealing it now holds 10.5 Bitcoin and 300 Ethereum, representing 43.6% of its treasury, with plans to go as high as 50%.

This bold move triggered a wave of retail momentum, crypto-aligned speculation, and a potential short squeeze in motion. Short interest remains notably elevated, and with Phase 2 trial news pending, bulls are betting this is more than just a one-day pop. Look for extended moves in after-hours, especially if Bitcoin or Ethereum spike or the company follows up with another press release.

Cocrystal Pharma (NASDAQ:COCP) impressed at the 9th International Calicivirus Conference with its podium presentation of CDI-988, its first-in-class oral antiviral for norovirus infection. President and Co-CEO Dr. Sam Lee highlighted Phase 1 data, a strong safety profile, and FDA IND clearance for a human challenge trial expected to begin by year-end.

CDI-988 was developed using Cocrystal’s proprietary structure-based drug discovery platform and targets a broad range of norovirus genogroups, notably GII.4 and GII.17, which are responsible for most outbreaks. With no current approved oral treatment for norovirus, COCP could be positioned for a first-mover advantage in this unmet market.

Polyrizon (NASDAQ:PLRZ) reported encouraging preclinical data for PL-14, its intranasal hydrogel-based allergy blocker, showing over 60% targeted deposition in the nasal vestibule, a critical site for airborne allergen interception. The study, done in partnership with Italy’s University of Parma, reinforces the company’s “capture & contain” approach for treating allergic rhinitis.

The allergy blocker market is expected to grow to $0.21 billion by 2033 and PLRZ is angling for a first-line, non-pharmaceutical treatment niche. The formulation’s favorable sprayability and practical self-administration profile further support its consumer viability.

HCW Biologics (NASDAQ:HCWB) is riding high after reporting strong non-human primate safety data for its second-generation T-cell engagers (TCEs), targeting solid tumors like pancreatic cancer and glioblastoma. The company’s proprietary TRBC platform aims to solve the efficacy, tolerability, and manufacturability challenges faced by first-gen TCEs.

CEO Dr. Hing C. Wong confirmed the company is now seeking corporate partners to advance clinical development. With 100% survival in preclinical tumor-bearing mice and no signs of cytokine storm in primates, HCWB’s program may draw attention in upcoming biopharma deal-making rounds.

Glucotrack (NASDAQ:GCTK) a medical tech firm focused on diabetes management, is prepping for a key visibility moment at the Q3 Virtual Investor Summit (Sep 16–17). No clinical data yet, but investor exposure could drive sentiment ahead of any future announcements.

Hong Kong-based Majestic Ideal Holdings (NASDAQ:MJID) received shareholder approval to officially change its name to “Ping An Biomedical Co., Ltd.”, a move the board says better reflects its strategic focus on healthcare innovation. While not a price-moving event on its own, the rebrand could precede shifts in business direction, potential partnerships, or M&A activity.

PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 247 is a third-party media provider and has been compensated by Microcap Advisory for providing ongoing LIXT and XHLD market outreach and other services. Please review our Full Disclaimer https://www.247marketnews.com/disclaimer/ . Please go to https://247marketnews.com/lixte-biotechnology/ for further LIXT and 247marketnews.com disclosure information.

The post Biotech Breakouts & Bitcoin Bets appeared first on 24/7 MarketNews .

For further details see: